HRH3 and delirium: We propose that central histamine is a significant player in all of the clinical features of delirium; while H1 and H2 histamine-targeted antihistamines should be treated with care, a centrally acting histamine H3 receptor antagonist, with appropriate diurnal pharmacokinetic properties, may provide a novel and effective strategy for preventing or combatting delirium.